Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development Article Swipe
Meir Bialer
,
Svein I. Johannessen
,
Matthias J. Koepp
,
Emilio Perucca
,
Piero Perucca
,
Torbjörn Tomson
,
H. Steve White
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1111/epi.18075
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1111/epi.18075
The 17th Eilat Conference on New Antiepileptic Drugs and Devices took place in Madrid, Spain on May 5–8, 2024. As usual, the core part of the conference consisted of presentations on investigational drugs at various stages of development for epilepsy‐related indications. Summaries of information on compounds in preclinical or early clinical development are included in an accompanying publication (Part I). In this article, we provide summaries for five compounds in more advanced clinical development, i.e. compounds for which some information on antiseizure activity in individuals with epilepsy is available. These investigational treatments include azetukalner (XEN1101), a potent, K V 7.2/7.3‐specific potassium channel opener in development for the treatment of focal seizures, generalized tonic–clonic seizures, and major depressive disorder; bexicaserin (LP352), a selective 5‐HT 2C receptor superagonist in development for the treatment of seizures associated with developmental and epileptic encephalopathies; radiprodil, a selective negative allosteric modulator of NR2B subunit‐containing N‐methyl‐D‐aspartate glutamate receptors, in development for the treatment of seizures and behavior manifestations associated with disorders caused by gain‐of‐function mutations in the GRIN1 , −2A , ‐2B , or ‐2D genes; soticlestat (TAK‐935), a selective inhibitor of cholesterol 24‐hydroxylase in development for the treatment of seizures associated with Dravet syndrome and Lennox–Gastaut syndrome; and STK‐001, an antisense oligonucleotide designed to upregulate Na v 1.1 protein expression and improve outcomes in individuals with Dravet syndrome. The diversity in mechanisms of action of these agents illustrates different approaches being pursued in the discovery of novel treatments for seizures and epilepsy. For two of the compounds discussed in this report (azetukalner and soticlestat), clinical evidence of efficacy has already been obtained in a randomized placebo‐controlled adjunctive‐therapy trial. For the other compounds, adequately powered placebo‐controlled efficacy trials have not been completed to date.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1111/epi.18075
- https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/epi.18075
- OA Status
- bronze
- Cited By
- 21
- References
- 51
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4401737164
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4401737164Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1111/epi.18075Digital Object Identifier
- Title
-
Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical developmentWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-08-22Full publication date if available
- Authors
-
Meir Bialer, Svein I. Johannessen, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve WhiteList of authors in order
- Landing page
-
https://doi.org/10.1111/epi.18075Publisher landing page
- PDF URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/epi.18075Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/epi.18075Direct OA link when available
- Concepts
-
Dravet syndrome, Epilepsy, Medicine, Drug development, Allosteric regulation, Allosteric modulator, Pharmacology, Seizure types, Neuroscience, Psychiatry, Receptor, Psychology, Drug, Internal medicineTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
21Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 18, 2024: 3Per-year citation counts (last 5 years)
- References (count)
-
51Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4401737164 |
|---|---|
| doi | https://doi.org/10.1111/epi.18075 |
| ids.doi | https://doi.org/10.1111/epi.18075 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/39171993 |
| ids.openalex | https://openalex.org/W4401737164 |
| fwci | 18.82040444 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000627 |
| mesh[1].descriptor_ui | D000927 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | therapeutic use |
| mesh[1].descriptor_name | Anticonvulsants |
| mesh[2].qualifier_ui | Q000188 |
| mesh[2].descriptor_ui | D004827 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | drug therapy |
| mesh[2].descriptor_name | Epilepsy |
| mesh[3].qualifier_ui | Q000235 |
| mesh[3].descriptor_ui | D004827 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | genetics |
| mesh[3].descriptor_name | Epilepsy |
| mesh[4].qualifier_ui | Q000188 |
| mesh[4].descriptor_ui | D012640 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | drug therapy |
| mesh[4].descriptor_name | Seizures |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D000076722 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Drug Development |
| mesh[6].qualifier_ui | Q000627 |
| mesh[6].descriptor_ui | D015507 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | therapeutic use |
| mesh[6].descriptor_name | Drugs, Investigational |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D000818 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Animals |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D006801 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Humans |
| mesh[9].qualifier_ui | Q000627 |
| mesh[9].descriptor_ui | D000927 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | therapeutic use |
| mesh[9].descriptor_name | Anticonvulsants |
| mesh[10].qualifier_ui | Q000188 |
| mesh[10].descriptor_ui | D004827 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | drug therapy |
| mesh[10].descriptor_name | Epilepsy |
| mesh[11].qualifier_ui | Q000235 |
| mesh[11].descriptor_ui | D004827 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | genetics |
| mesh[11].descriptor_name | Epilepsy |
| mesh[12].qualifier_ui | Q000188 |
| mesh[12].descriptor_ui | D012640 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | drug therapy |
| mesh[12].descriptor_name | Seizures |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D000076722 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Drug Development |
| mesh[14].qualifier_ui | Q000627 |
| mesh[14].descriptor_ui | D015507 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | therapeutic use |
| mesh[14].descriptor_name | Drugs, Investigational |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D000818 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Animals |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D006801 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Humans |
| mesh[17].qualifier_ui | Q000627 |
| mesh[17].descriptor_ui | D000927 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | therapeutic use |
| mesh[17].descriptor_name | Anticonvulsants |
| mesh[18].qualifier_ui | Q000188 |
| mesh[18].descriptor_ui | D004827 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | drug therapy |
| mesh[18].descriptor_name | Epilepsy |
| mesh[19].qualifier_ui | Q000235 |
| mesh[19].descriptor_ui | D004827 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | genetics |
| mesh[19].descriptor_name | Epilepsy |
| mesh[20].qualifier_ui | Q000188 |
| mesh[20].descriptor_ui | D012640 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | drug therapy |
| mesh[20].descriptor_name | Seizures |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D000076722 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Drug Development |
| mesh[22].qualifier_ui | Q000627 |
| mesh[22].descriptor_ui | D015507 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | therapeutic use |
| mesh[22].descriptor_name | Drugs, Investigational |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D000818 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Animals |
| type | article |
| title | Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development |
| biblio.issue | 10 |
| biblio.volume | 65 |
| biblio.last_page | 2882 |
| biblio.first_page | 2858 |
| topics[0].id | https://openalex.org/T10094 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998000264167786 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2738 |
| topics[0].subfield.display_name | Psychiatry and Mental health |
| topics[0].display_name | Epilepsy research and treatment |
| topics[1].id | https://openalex.org/T10077 |
| topics[1].field.id | https://openalex.org/fields/28 |
| topics[1].field.display_name | Neuroscience |
| topics[1].score | 0.9991000294685364 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2804 |
| topics[1].subfield.display_name | Cellular and Molecular Neuroscience |
| topics[1].display_name | Neuroscience and Neuropharmacology Research |
| topics[2].id | https://openalex.org/T12229 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9966999888420105 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2735 |
| topics[2].subfield.display_name | Pediatrics, Perinatology and Child Health |
| topics[2].display_name | Pharmacological Effects and Toxicity Studies |
| is_xpac | False |
| apc_list.value | 3950 |
| apc_list.currency | USD |
| apc_list.value_usd | 3950 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2780623815 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8949906826019287 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1255956 |
| concepts[0].display_name | Dravet syndrome |
| concepts[1].id | https://openalex.org/C2778186239 |
| concepts[1].level | 2 |
| concepts[1].score | 0.7333933115005493 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q41571 |
| concepts[1].display_name | Epilepsy |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.5527165532112122 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C64903051 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5114209055900574 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q2198549 |
| concepts[3].display_name | Drug development |
| concepts[4].id | https://openalex.org/C166342909 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5031470656394958 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q845326 |
| concepts[4].display_name | Allosteric regulation |
| concepts[5].id | https://openalex.org/C2776038425 |
| concepts[5].level | 4 |
| concepts[5].score | 0.454764187335968 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2649417 |
| concepts[5].display_name | Allosteric modulator |
| concepts[6].id | https://openalex.org/C98274493 |
| concepts[6].level | 1 |
| concepts[6].score | 0.42360588908195496 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[6].display_name | Pharmacology |
| concepts[7].id | https://openalex.org/C2780874087 |
| concepts[7].level | 3 |
| concepts[7].score | 0.41141384840011597 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q7447057 |
| concepts[7].display_name | Seizure types |
| concepts[8].id | https://openalex.org/C169760540 |
| concepts[8].level | 1 |
| concepts[8].score | 0.3607865869998932 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q207011 |
| concepts[8].display_name | Neuroscience |
| concepts[9].id | https://openalex.org/C118552586 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3077579438686371 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q7867 |
| concepts[9].display_name | Psychiatry |
| concepts[10].id | https://openalex.org/C170493617 |
| concepts[10].level | 2 |
| concepts[10].score | 0.3043971657752991 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[10].display_name | Receptor |
| concepts[11].id | https://openalex.org/C15744967 |
| concepts[11].level | 0 |
| concepts[11].score | 0.27836406230926514 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q9418 |
| concepts[11].display_name | Psychology |
| concepts[12].id | https://openalex.org/C2780035454 |
| concepts[12].level | 2 |
| concepts[12].score | 0.24654874205589294 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q8386 |
| concepts[12].display_name | Drug |
| concepts[13].id | https://openalex.org/C126322002 |
| concepts[13].level | 1 |
| concepts[13].score | 0.21395546197891235 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[13].display_name | Internal medicine |
| keywords[0].id | https://openalex.org/keywords/dravet-syndrome |
| keywords[0].score | 0.8949906826019287 |
| keywords[0].display_name | Dravet syndrome |
| keywords[1].id | https://openalex.org/keywords/epilepsy |
| keywords[1].score | 0.7333933115005493 |
| keywords[1].display_name | Epilepsy |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.5527165532112122 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/drug-development |
| keywords[3].score | 0.5114209055900574 |
| keywords[3].display_name | Drug development |
| keywords[4].id | https://openalex.org/keywords/allosteric-regulation |
| keywords[4].score | 0.5031470656394958 |
| keywords[4].display_name | Allosteric regulation |
| keywords[5].id | https://openalex.org/keywords/allosteric-modulator |
| keywords[5].score | 0.454764187335968 |
| keywords[5].display_name | Allosteric modulator |
| keywords[6].id | https://openalex.org/keywords/pharmacology |
| keywords[6].score | 0.42360588908195496 |
| keywords[6].display_name | Pharmacology |
| keywords[7].id | https://openalex.org/keywords/seizure-types |
| keywords[7].score | 0.41141384840011597 |
| keywords[7].display_name | Seizure types |
| keywords[8].id | https://openalex.org/keywords/neuroscience |
| keywords[8].score | 0.3607865869998932 |
| keywords[8].display_name | Neuroscience |
| keywords[9].id | https://openalex.org/keywords/psychiatry |
| keywords[9].score | 0.3077579438686371 |
| keywords[9].display_name | Psychiatry |
| keywords[10].id | https://openalex.org/keywords/receptor |
| keywords[10].score | 0.3043971657752991 |
| keywords[10].display_name | Receptor |
| keywords[11].id | https://openalex.org/keywords/psychology |
| keywords[11].score | 0.27836406230926514 |
| keywords[11].display_name | Psychology |
| keywords[12].id | https://openalex.org/keywords/drug |
| keywords[12].score | 0.24654874205589294 |
| keywords[12].display_name | Drug |
| keywords[13].id | https://openalex.org/keywords/internal-medicine |
| keywords[13].score | 0.21395546197891235 |
| keywords[13].display_name | Internal medicine |
| language | en |
| locations[0].id | doi:10.1111/epi.18075 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S203153751 |
| locations[0].source.issn | 0013-9580, 1528-1157, 1528-1167 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0013-9580 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Epilepsia |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].license | |
| locations[0].pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/epi.18075 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Epilepsia |
| locations[0].landing_page_url | https://doi.org/10.1111/epi.18075 |
| locations[1].id | pmid:39171993 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Epilepsia |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/39171993 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5001346835 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-2046-4171 |
| authorships[0].author.display_name | Meir Bialer |
| authorships[0].countries | IL |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I197251160 |
| authorships[0].affiliations[0].raw_affiliation_string | Institute for Drug Research, Faculty of Medicine and David R. Bloom Center for Pharmacy, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel |
| authorships[0].institutions[0].id | https://openalex.org/I197251160 |
| authorships[0].institutions[0].ror | https://ror.org/03qxff017 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I197251160 |
| authorships[0].institutions[0].country_code | IL |
| authorships[0].institutions[0].display_name | Hebrew University of Jerusalem |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Meir Bialer |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Institute for Drug Research, Faculty of Medicine and David R. Bloom Center for Pharmacy, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel |
| authorships[1].author.id | https://openalex.org/A5041638264 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-7087-6655 |
| authorships[1].author.display_name | Svein I. Johannessen |
| authorships[1].countries | NO |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1281400175 |
| authorships[1].affiliations[0].raw_affiliation_string | Oslo University Hospital, member of the European Reference Network EpiCare, Oslo, Norway |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I1281400175 |
| authorships[1].affiliations[1].raw_affiliation_string | Section for Clinical Pharmacology, Department of Pharmacology, Oslo University Hospital, Oslo, Norway |
| authorships[1].affiliations[2].raw_affiliation_string | National Center for Epilepsy, Sandvika, Norway |
| authorships[1].institutions[0].id | https://openalex.org/I1281400175 |
| authorships[1].institutions[0].ror | https://ror.org/00j9c2840 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I1281400175 |
| authorships[1].institutions[0].country_code | NO |
| authorships[1].institutions[0].display_name | Oslo University Hospital |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Svein I. Johannessen |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | National Center for Epilepsy, Sandvika, Norway, Oslo University Hospital, member of the European Reference Network EpiCare, Oslo, Norway, Section for Clinical Pharmacology, Department of Pharmacology, Oslo University Hospital, Oslo, Norway |
| authorships[2].author.id | https://openalex.org/A5059608304 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-4277-8000 |
| authorships[2].author.display_name | Matthias J. Koepp |
| authorships[2].countries | GB |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210151618, https://openalex.org/I45129253 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Clinical and Experimental Epilepsy, University College London Queen Square Institute of Neurology, London, UK |
| authorships[2].institutions[0].id | https://openalex.org/I4210151618 |
| authorships[2].institutions[0].ror | https://ror.org/048b34d51 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I1340918713, https://openalex.org/I4210151618 |
| authorships[2].institutions[0].country_code | GB |
| authorships[2].institutions[0].display_name | National Hospital for Neurology and Neurosurgery |
| authorships[2].institutions[1].id | https://openalex.org/I45129253 |
| authorships[2].institutions[1].ror | https://ror.org/02jx3x895 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I124357947, https://openalex.org/I45129253 |
| authorships[2].institutions[1].country_code | GB |
| authorships[2].institutions[1].display_name | University College London |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Matthias J. Koepp |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Clinical and Experimental Epilepsy, University College London Queen Square Institute of Neurology, London, UK |
| authorships[3].author.id | https://openalex.org/A5040883137 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-8703-223X |
| authorships[3].author.display_name | Emilio Perucca |
| authorships[3].countries | AU |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I165779595, https://openalex.org/I4210163497 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia |
| authorships[3].affiliations[1].institution_ids | https://openalex.org/I56590836 |
| authorships[3].affiliations[1].raw_affiliation_string | Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia |
| authorships[3].institutions[0].id | https://openalex.org/I4210163497 |
| authorships[3].institutions[0].ror | https://ror.org/05dbj6g52 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210163497 |
| authorships[3].institutions[0].country_code | AU |
| authorships[3].institutions[0].display_name | Austin Health |
| authorships[3].institutions[1].id | https://openalex.org/I56590836 |
| authorships[3].institutions[1].ror | https://ror.org/02bfwt286 |
| authorships[3].institutions[1].type | education |
| authorships[3].institutions[1].lineage | https://openalex.org/I56590836 |
| authorships[3].institutions[1].country_code | AU |
| authorships[3].institutions[1].display_name | Monash University |
| authorships[3].institutions[2].id | https://openalex.org/I165779595 |
| authorships[3].institutions[2].ror | https://ror.org/01ej9dk98 |
| authorships[3].institutions[2].type | education |
| authorships[3].institutions[2].lineage | https://openalex.org/I165779595 |
| authorships[3].institutions[2].country_code | AU |
| authorships[3].institutions[2].display_name | The University of Melbourne |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Emilio Perucca |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia, Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia |
| authorships[4].author.id | https://openalex.org/A5017253540 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-7855-7066 |
| authorships[4].author.display_name | Piero Perucca |
| authorships[4].countries | AU |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I165779595, https://openalex.org/I4210163497 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I1320473756 |
| authorships[4].affiliations[1].raw_affiliation_string | Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia |
| authorships[4].affiliations[2].institution_ids | https://openalex.org/I4210163497 |
| authorships[4].affiliations[2].raw_affiliation_string | Bladin-Berkovic Comprehensive Epilepsy Program, Department of Neurology, Austin Health, Melbourne, Victoria, Australia |
| authorships[4].affiliations[3].institution_ids | https://openalex.org/I56590836 |
| authorships[4].affiliations[3].raw_affiliation_string | Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia |
| authorships[4].affiliations[4].institution_ids | https://openalex.org/I4210163178 |
| authorships[4].affiliations[4].raw_affiliation_string | Department of Neurology, Alfred Health, Melbourne, Victoria, Australia |
| authorships[4].institutions[0].id | https://openalex.org/I4210163178 |
| authorships[4].institutions[0].ror | https://ror.org/04scfb908 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210163178 |
| authorships[4].institutions[0].country_code | AU |
| authorships[4].institutions[0].display_name | Alfred Health |
| authorships[4].institutions[1].id | https://openalex.org/I4210163497 |
| authorships[4].institutions[1].ror | https://ror.org/05dbj6g52 |
| authorships[4].institutions[1].type | healthcare |
| authorships[4].institutions[1].lineage | https://openalex.org/I4210163497 |
| authorships[4].institutions[1].country_code | AU |
| authorships[4].institutions[1].display_name | Austin Health |
| authorships[4].institutions[2].id | https://openalex.org/I56590836 |
| authorships[4].institutions[2].ror | https://ror.org/02bfwt286 |
| authorships[4].institutions[2].type | education |
| authorships[4].institutions[2].lineage | https://openalex.org/I56590836 |
| authorships[4].institutions[2].country_code | AU |
| authorships[4].institutions[2].display_name | Monash University |
| authorships[4].institutions[3].id | https://openalex.org/I1320473756 |
| authorships[4].institutions[3].ror | https://ror.org/005bvs909 |
| authorships[4].institutions[3].type | healthcare |
| authorships[4].institutions[3].lineage | https://openalex.org/I1320473756, https://openalex.org/I4210158168 |
| authorships[4].institutions[3].country_code | AU |
| authorships[4].institutions[3].display_name | The Royal Melbourne Hospital |
| authorships[4].institutions[4].id | https://openalex.org/I165779595 |
| authorships[4].institutions[4].ror | https://ror.org/01ej9dk98 |
| authorships[4].institutions[4].type | education |
| authorships[4].institutions[4].lineage | https://openalex.org/I165779595 |
| authorships[4].institutions[4].country_code | AU |
| authorships[4].institutions[4].display_name | The University of Melbourne |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Piero Perucca |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Bladin-Berkovic Comprehensive Epilepsy Program, Department of Neurology, Austin Health, Melbourne, Victoria, Australia, Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia, Department of Neurology, Alfred Health, Melbourne, Victoria, Australia, Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia, Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia |
| authorships[5].author.id | https://openalex.org/A5019416797 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-0554-5352 |
| authorships[5].author.display_name | Torbjörn Tomson |
| authorships[5].countries | SE |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I28166907 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden |
| authorships[5].institutions[0].id | https://openalex.org/I28166907 |
| authorships[5].institutions[0].ror | https://ror.org/056d84691 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I28166907 |
| authorships[5].institutions[0].country_code | SE |
| authorships[5].institutions[0].display_name | Karolinska Institutet |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Torbjörn Tomson |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden |
| authorships[6].author.id | https://openalex.org/A5088706930 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-4550-4408 |
| authorships[6].author.display_name | H. Steve White |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I201448701 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Pharmacy, Center for Epilepsy Drug Discovery, School of Pharmacy, University of Washington, Seattle, Washington, USA |
| authorships[6].institutions[0].id | https://openalex.org/I201448701 |
| authorships[6].institutions[0].ror | https://ror.org/00cvxb145 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I201448701 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | University of Washington |
| authorships[6].author_position | last |
| authorships[6].raw_author_name | H. Steve White |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Pharmacy, Center for Epilepsy Drug Discovery, School of Pharmacy, University of Washington, Seattle, Washington, USA |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/epi.18075 |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10094 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998000264167786 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2738 |
| primary_topic.subfield.display_name | Psychiatry and Mental health |
| primary_topic.display_name | Epilepsy research and treatment |
| related_works | https://openalex.org/W2744779241, https://openalex.org/W2972923340, https://openalex.org/W4241434933, https://openalex.org/W2413283532, https://openalex.org/W2954309427, https://openalex.org/W3032032492, https://openalex.org/W2100024810, https://openalex.org/W1581940992, https://openalex.org/W1584162107, https://openalex.org/W2103933289 |
| cited_by_count | 21 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 18 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 3 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1111/epi.18075 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S203153751 |
| best_oa_location.source.issn | 0013-9580, 1528-1157, 1528-1167 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0013-9580 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Epilepsia |
| best_oa_location.source.host_organization | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_name | Wiley |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/epi.18075 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Epilepsia |
| best_oa_location.landing_page_url | https://doi.org/10.1111/epi.18075 |
| primary_location.id | doi:10.1111/epi.18075 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S203153751 |
| primary_location.source.issn | 0013-9580, 1528-1157, 1528-1167 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0013-9580 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Epilepsia |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.license | |
| primary_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/epi.18075 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Epilepsia |
| primary_location.landing_page_url | https://doi.org/10.1111/epi.18075 |
| publication_date | 2024-08-22 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W4400650384, https://openalex.org/W4313281272, https://openalex.org/W2408529313, https://openalex.org/W3133877026, https://openalex.org/W4291019955, https://openalex.org/W4235634374, https://openalex.org/W2898181423, https://openalex.org/W4387439518, https://openalex.org/W4394598647, https://openalex.org/W2604155526, https://openalex.org/W2282633450, https://openalex.org/W6636710930, https://openalex.org/W6836704315, https://openalex.org/W6603498413, https://openalex.org/W2124134368, https://openalex.org/W2618794745, https://openalex.org/W3199969885, https://openalex.org/W3007690701, https://openalex.org/W2033179944, https://openalex.org/W4385255593, https://openalex.org/W4393182401, https://openalex.org/W3038068929, https://openalex.org/W2003171800, https://openalex.org/W1991816820, https://openalex.org/W1553535483, https://openalex.org/W6959359964, https://openalex.org/W3080983898, https://openalex.org/W4394599473, https://openalex.org/W1992465104, https://openalex.org/W2056033864, https://openalex.org/W4407067875, https://openalex.org/W4407067941, https://openalex.org/W4387157852, https://openalex.org/W4394599518, https://openalex.org/W3024330278, https://openalex.org/W4308189422, https://openalex.org/W4389991086, https://openalex.org/W4367303759, https://openalex.org/W4367303714, https://openalex.org/W1564863670, https://openalex.org/W2050451211, https://openalex.org/W3081439212, https://openalex.org/W6921373106, https://openalex.org/W3040712690, https://openalex.org/W3049392649, https://openalex.org/W4391754477, https://openalex.org/W6861275809, https://openalex.org/W4381331530, https://openalex.org/W6853921008, https://openalex.org/W3011140744, https://openalex.org/W4391754373 |
| referenced_works_count | 51 |
| abstract_inverted_index., | 172, 174, 176 |
| abstract_inverted_index.K | 98 |
| abstract_inverted_index.V | 99 |
| abstract_inverted_index.a | 96, 121, 141, 182, 268 |
| abstract_inverted_index.v | 211 |
| abstract_inverted_index.2C | 124 |
| abstract_inverted_index.As | 20 |
| abstract_inverted_index.In | 61 |
| abstract_inverted_index.Na | 210 |
| abstract_inverted_index.an | 56, 204 |
| abstract_inverted_index.at | 34 |
| abstract_inverted_index.by | 166 |
| abstract_inverted_index.in | 13, 47, 55, 70, 84, 104, 127, 152, 169, 188, 218, 225, 237, 253, 267 |
| abstract_inverted_index.is | 88 |
| abstract_inverted_index.of | 25, 29, 37, 43, 109, 132, 146, 157, 185, 193, 227, 229, 240, 249, 261 |
| abstract_inverted_index.on | 5, 16, 31, 45, 81 |
| abstract_inverted_index.or | 49, 177 |
| abstract_inverted_index.to | 208, 286 |
| abstract_inverted_index.we | 64 |
| abstract_inverted_index.1.1 | 212 |
| abstract_inverted_index.For | 247, 273 |
| abstract_inverted_index.I). | 60 |
| abstract_inverted_index.May | 17 |
| abstract_inverted_index.New | 6 |
| abstract_inverted_index.The | 1, 223 |
| abstract_inverted_index.and | 9, 115, 137, 159, 199, 202, 215, 245, 257 |
| abstract_inverted_index.are | 53 |
| abstract_inverted_index.for | 39, 67, 77, 106, 129, 154, 190, 243 |
| abstract_inverted_index.has | 263 |
| abstract_inverted_index.not | 283 |
| abstract_inverted_index.the | 22, 26, 107, 130, 155, 170, 191, 238, 250, 274 |
| abstract_inverted_index.two | 248 |
| abstract_inverted_index.17th | 2 |
| abstract_inverted_index.NR2B | 147 |
| abstract_inverted_index.been | 265, 284 |
| abstract_inverted_index.core | 23 |
| abstract_inverted_index.five | 68 |
| abstract_inverted_index.have | 282 |
| abstract_inverted_index.i.e. | 75 |
| abstract_inverted_index.more | 71 |
| abstract_inverted_index.part | 24 |
| abstract_inverted_index.some | 79 |
| abstract_inverted_index.this | 62, 254 |
| abstract_inverted_index.took | 11 |
| abstract_inverted_index.with | 86, 135, 163, 196, 220 |
| abstract_inverted_index.(Part | 59 |
| abstract_inverted_index.2024. | 19 |
| abstract_inverted_index.Drugs | 8 |
| abstract_inverted_index.Eilat | 3 |
| abstract_inverted_index.GRIN1 | 171 |
| abstract_inverted_index.Spain | 15 |
| abstract_inverted_index.These | 90 |
| abstract_inverted_index.being | 235 |
| abstract_inverted_index.date. | 287 |
| abstract_inverted_index.drugs | 33 |
| abstract_inverted_index.early | 50 |
| abstract_inverted_index.focal | 110 |
| abstract_inverted_index.major | 116 |
| abstract_inverted_index.novel | 241 |
| abstract_inverted_index.other | 275 |
| abstract_inverted_index.place | 12 |
| abstract_inverted_index.these | 230 |
| abstract_inverted_index.which | 78 |
| abstract_inverted_index.‐2B | 175 |
| abstract_inverted_index.‐2D | 178 |
| abstract_inverted_index.−2A | 173 |
| abstract_inverted_index.5‐HT | 123 |
| abstract_inverted_index.5–8, | 18 |
| abstract_inverted_index.Dravet | 197, 221 |
| abstract_inverted_index.action | 228 |
| abstract_inverted_index.agents | 231 |
| abstract_inverted_index.caused | 165 |
| abstract_inverted_index.genes; | 179 |
| abstract_inverted_index.opener | 103 |
| abstract_inverted_index.report | 255 |
| abstract_inverted_index.stages | 36 |
| abstract_inverted_index.trial. | 272 |
| abstract_inverted_index.trials | 281 |
| abstract_inverted_index.usual, | 21 |
| abstract_inverted_index.Devices | 10 |
| abstract_inverted_index.Madrid, | 14 |
| abstract_inverted_index.already | 264 |
| abstract_inverted_index.channel | 102 |
| abstract_inverted_index.improve | 216 |
| abstract_inverted_index.include | 93 |
| abstract_inverted_index.potent, | 97 |
| abstract_inverted_index.powered | 278 |
| abstract_inverted_index.protein | 213 |
| abstract_inverted_index.provide | 65 |
| abstract_inverted_index.pursued | 236 |
| abstract_inverted_index.various | 35 |
| abstract_inverted_index.(LP352), | 120 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.activity | 83 |
| abstract_inverted_index.advanced | 72 |
| abstract_inverted_index.article, | 63 |
| abstract_inverted_index.behavior | 160 |
| abstract_inverted_index.clinical | 51, 73, 259 |
| abstract_inverted_index.designed | 207 |
| abstract_inverted_index.efficacy | 262, 280 |
| abstract_inverted_index.epilepsy | 87 |
| abstract_inverted_index.evidence | 260 |
| abstract_inverted_index.included | 54 |
| abstract_inverted_index.negative | 143 |
| abstract_inverted_index.obtained | 266 |
| abstract_inverted_index.outcomes | 217 |
| abstract_inverted_index.receptor | 125 |
| abstract_inverted_index.seizures | 133, 158, 194, 244 |
| abstract_inverted_index.syndrome | 198 |
| abstract_inverted_index.Summaries | 42 |
| abstract_inverted_index.antisense | 205 |
| abstract_inverted_index.completed | 285 |
| abstract_inverted_index.compounds | 46, 69, 76, 251 |
| abstract_inverted_index.consisted | 28 |
| abstract_inverted_index.different | 233 |
| abstract_inverted_index.discovery | 239 |
| abstract_inverted_index.discussed | 252 |
| abstract_inverted_index.disorder; | 118 |
| abstract_inverted_index.disorders | 164 |
| abstract_inverted_index.diversity | 224 |
| abstract_inverted_index.epilepsy. | 246 |
| abstract_inverted_index.epileptic | 138 |
| abstract_inverted_index.glutamate | 150 |
| abstract_inverted_index.inhibitor | 184 |
| abstract_inverted_index.modulator | 145 |
| abstract_inverted_index.mutations | 168 |
| abstract_inverted_index.potassium | 101 |
| abstract_inverted_index.seizures, | 111, 114 |
| abstract_inverted_index.selective | 122, 142, 183 |
| abstract_inverted_index.summaries | 66 |
| abstract_inverted_index.syndrome. | 222 |
| abstract_inverted_index.syndrome; | 201 |
| abstract_inverted_index.treatment | 108, 131, 156, 192 |
| abstract_inverted_index.(XEN1101), | 95 |
| abstract_inverted_index.Conference | 4 |
| abstract_inverted_index.STK‐001, | 203 |
| abstract_inverted_index.adequately | 277 |
| abstract_inverted_index.allosteric | 144 |
| abstract_inverted_index.approaches | 234 |
| abstract_inverted_index.associated | 134, 162, 195 |
| abstract_inverted_index.available. | 89 |
| abstract_inverted_index.compounds, | 276 |
| abstract_inverted_index.conference | 27 |
| abstract_inverted_index.depressive | 117 |
| abstract_inverted_index.expression | 214 |
| abstract_inverted_index.mechanisms | 226 |
| abstract_inverted_index.randomized | 269 |
| abstract_inverted_index.receptors, | 151 |
| abstract_inverted_index.treatments | 92, 242 |
| abstract_inverted_index.upregulate | 209 |
| abstract_inverted_index.antiseizure | 82 |
| abstract_inverted_index.azetukalner | 94 |
| abstract_inverted_index.bexicaserin | 119 |
| abstract_inverted_index.cholesterol | 186 |
| abstract_inverted_index.development | 38, 52, 105, 128, 153, 189 |
| abstract_inverted_index.generalized | 112 |
| abstract_inverted_index.illustrates | 232 |
| abstract_inverted_index.individuals | 85, 219 |
| abstract_inverted_index.information | 44, 80 |
| abstract_inverted_index.preclinical | 48 |
| abstract_inverted_index.publication | 58 |
| abstract_inverted_index.radiprodil, | 140 |
| abstract_inverted_index.soticlestat | 180 |
| abstract_inverted_index.(TAK‐935), | 181 |
| abstract_inverted_index.(azetukalner | 256 |
| abstract_inverted_index.accompanying | 57 |
| abstract_inverted_index.development, | 74 |
| abstract_inverted_index.indications. | 41 |
| abstract_inverted_index.superagonist | 126 |
| abstract_inverted_index.Antiepileptic | 7 |
| abstract_inverted_index.developmental | 136 |
| abstract_inverted_index.presentations | 30 |
| abstract_inverted_index.soticlestat), | 258 |
| abstract_inverted_index.manifestations | 161 |
| abstract_inverted_index.tonic–clonic | 113 |
| abstract_inverted_index.investigational | 32, 91 |
| abstract_inverted_index.oligonucleotide | 206 |
| abstract_inverted_index.24‐hydroxylase | 187 |
| abstract_inverted_index.Lennox–Gastaut | 200 |
| abstract_inverted_index.encephalopathies; | 139 |
| abstract_inverted_index.7.2/7.3‐specific | 100 |
| abstract_inverted_index.epilepsy‐related | 40 |
| abstract_inverted_index.adjunctive‐therapy | 271 |
| abstract_inverted_index.gain‐of‐function | 167 |
| abstract_inverted_index.placebo‐controlled | 270, 279 |
| abstract_inverted_index.subunit‐containing | 148 |
| abstract_inverted_index.N‐methyl‐D‐aspartate | 149 |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 96 |
| corresponding_author_ids | https://openalex.org/A5001346835 |
| countries_distinct_count | 6 |
| institutions_distinct_count | 7 |
| corresponding_institution_ids | https://openalex.org/I197251160 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.6800000071525574 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.99067278 |
| citation_normalized_percentile.is_in_top_1_percent | True |
| citation_normalized_percentile.is_in_top_10_percent | True |